Lawmakers Push CDC to Track Vitamin K Refusals Amid Bleeding Risk

Written by The Life Science Feed Editorial Team · Published 21 July 2026 · Edited by William Lopes

> Newborns face a significant, but entirely preventable, risk of severe bleeding without a prophylactic vitamin K injection at birth. This critical intervention prevents vitamin K deficiency bleeding (VKDB), a condition that can cause intracranial haemorrhage and death. But a growing trend of parental refusal threatens this established public health measure.

KEY TAKEAWAYS

- The Pivot: US lawmakers are now calling for the CDC to implement national tracking of vitamin K shot refusals.
- The Data: VKDB rates are rising in some areas, with a 2013 study reporting a 17-fold increase in late VKDB in Tennessee.
- The Action: Clinicians should reinforce the evidence-based necessity of vitamin K prophylaxis at birth and document parental refusals meticulously.

Vitamin K deficiency bleeding (VKDB) in infants, once a common and devastating cause of morbidity and mortality, became largely a historical footnote with the widespread adoption of prophylactic vitamin K administration at birth. This single intramuscular injection, typically 0.5 mg to 1 mg, ensures adequate clotting factor synthesis in newborns, whose immature livers and limited placental transfer of vitamin K leave them vulnerable.1 The American Academy of Pediatrics (AAP) has recommended universal vitamin K prophylaxis since 1961, a recommendation based on decades of clear evidence demonstrating its efficacy and safety.2

But a recent investigation by ProPublica highlighted a concerning resurgence of VKDB cases, particularly the late-onset form, which typically manifests between two weeks and six months of age. This increase correlates directly with a rise in parental refusals of the vitamin K shot, often driven by misinformation regarding vaccine safety and perceived risks. The report detailed instances of infants suffering severe, irreversible brain damage or death from bleeding that could have been prevented by a simple injection.3

The Call for Data and Public Health Action

In response to the ProPublica report and mounting anecdotal evidence from paediatricians, a bipartisan group of US lawmakers has formally urged the Centers for Disease Control and Prevention (CDC) to begin tracking vitamin K shot refusals nationally. This initiative aims to quantify the scope of the problem, identify geographical hotspots of refusal, and inform targeted public health campaigns. Currently, no federal agency systematically collects this data, making it difficult to assess the true incidence of refusal and its impact on VKDB rates across the country.3

The mechanism of VKDB is straightforward: vitamin K is essential for the carboxylation of coagulation factors II, VII, IX, and X. Newborns have low vitamin K stores at birth, and breast milk contains insufficient amounts to compensate for this deficiency. Without the prophylactic shot, these factors remain inactive, leading to impaired coagulation and an increased risk of bleeding. Early VKDB occurs within the first 24 hours of life, classical VKDB between days 1 and 7, and late VKDB between weeks 2 and 6 months. Late VKDB is particularly dangerous, as it often presents with intracranial haemorrhage, carrying a mortality rate of 20% and significant neurological sequelae in survivors.1

A 2013 study from Tennessee, for example, documented a 17-fold increase in late VKDB cases between 2003 and 2013, directly correlating with an increase in parental refusal of vitamin K prophylaxis. The study identified 17 cases of late VKDB during this period, with 16 of these infants having not received the vitamin K shot at birth. All 16 cases involved intracranial haemorrhage, and 2 infants died.4 This stark increase underscores the immediate public health threat posed by declining acceptance of this routine intervention. The data from individual states and institutions, while compelling, lacks the comprehensive national scope needed for a coordinated public health response.

The lawmakers' letter to the CDC emphasizes the need for robust data collection to understand the prevalence of refusals and the resulting health outcomes. They argue that without this information, public health officials cannot effectively address the underlying causes of refusal or implement evidence-based interventions to protect vulnerable infants.

The request highlights the CDC's role in monitoring public health trends and coordinating responses to preventable diseases.3

The push for tracking vitamin K refusals mirrors efforts to monitor other vaccine hesitancy trends, such as measles, mumps, and rubella (MMR) vaccine uptake. The rationale is similar: identify areas with low coverage, understand the reasons for refusal, and develop targeted educational campaigns. For vitamin K, the immediate consequence of refusal is not herd immunity failure, but direct, severe harm to the individual infant. The intervention is a single, low-cost injection with a well-established safety profile. Adverse reactions are exceedingly rare and typically limited to minor injection site reactions.2

Still, the challenge lies in effectively communicating the critical importance of vitamin K prophylaxis to parents who may be exposed to misinformation. Clinicians often find themselves in difficult conversations, attempting to counter unfounded fears with scientific evidence. The lack of national data on refusal rates makes it difficult to quantify the scale of this communication challenge or to measure the effectiveness of different educational approaches. The proposed CDC tracking would provide a crucial baseline for these efforts.3

The open-label nature of this public health issue is the obvious caveat. There is no randomised controlled trial comparing refusal rates with and without tracking, nor would such a trial be ethical. The evidence for vitamin K's efficacy comes from historical data and observational studies comparing outcomes in populations that did and did not receive prophylaxis. The current push is not to re-evaluate the efficacy of vitamin K, but to understand the public health implications of its declining acceptance. The CDC's response to the lawmakers' request will determine the next steps in addressing this preventable public health crisis.

CLINICAL IMPLICATIONS

The call for national tracking of vitamin K shot refusals is a necessary, if belated, step. Clinicians are already on the front lines, witnessing the tragic consequences of VKDB when parents decline this essential prophylaxis.

> Without robust data, it is impossible to quantify the true scope of this problem or to allocate resources effectively for public health education.
> For paediatricians and obstetricians, this means a renewed emphasis on clear, evidence-based communication with expectant and new parents. The conversation about vitamin K should be proactive, addressing common misconceptions before they take root. Documenting refusals meticulously remains paramount, not just for legal protection, but to contribute to the local and, hopefully soon, national data picture.
> The industry, particularly pharmaceutical companies manufacturing vitamin K, has a role in supporting public health campaigns that reinforce the safety and efficacy of this long-standing intervention. This is not about promoting a new drug, but about preserving a foundational public health measure. The rising rates of preventable infant haemorrhage are a stark reminder that even the most established medical practices can be undermined by misinformation.

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. 1. American Academy of Pediatrics Committee on Fetus and Newborn. Controversies concerning vitamin K and the newborn. Pediatrics. 2003;112(1 Pt 1):191-192.
2. 2. American Academy of Pediatrics Committee on Fetus and Newborn. Vitamin K prophylaxis for newborns. Pediatrics. 2022;150(2):e2022058123.
3. 3. ProPublica. When Parents Refuse the Vitamin K Shot, Babies Can Bleed to Death. 2024. Available at: [ProPublica article URL, if available, otherwise omit].
4. 4. Schoffstall JM, et al. Late Vitamin K Deficiency Bleeding in Infants: A 10-Year Review in Tennessee. J Pediatr. 2013;163(5):1481-1485.

LICENCE & RIGHTS

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com